Here, HL-60 (FAB M2 14% in AML; TP53/CDKN2A/NRASmut) and OCI-AML3 (FAB M4 20% in AML; DNMT3Amut, NPMc +) cell lines were chosen to cover an important part of AML patients with non-assigned therapy [in contrast to it is the case of FAB-M3] [29, 30]. Here, CDKN2A is linked to acute myeloid leukemia.